Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
24 Marzo 2022 - 5:30AM
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a
biopharmaceutical company developing and commercializing specialty
products for allergy, opioid overdose, respiratory and inflammatory
disease, today announced that it will host an investor conference
call on Thursday, March 31, 2022 at 2 p.m. Pacific Time to discuss
its financial and operating results for the fourth quarter and full
year 2021 as well as provide a business update. The company’s press
release concerning its fourth quarter and 2021 financial results is
expected to be available after 1 p.m. Pacific Time on March 31,
2022, and on its website. The company also expects to file its
annual report on Form 10-K for the year ended December 31, 2021 on
that date.
Event: Adamis Pharmaceuticals Fourth Quarter and Full Year 2021
Financial Results Conference CallDate: Thursday, March 31,
2022Time: 2 p.m. PT (5 p.m. ET)U.S. Dial-in (Toll Free):
1-877-423-9813Toll/International Dial-in: 1-201-689-8573Conference
ID: 13727967
Dennis J. Carlo, Ph.D., President and CEO of Adamis, will host
the call along with other members of the management team. The call
is open to the public and will provide an update on recent
developments, events that have taken place during the year, and
certain goals for future periods. Forward-looking statements
concerning expectations regarding future company performance may be
made during the conference call.
A live audio webcast of the conference call will also be
available via this link, with a replay available shortly after the
live event.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company primarily focused on developing and
commercializing products in various therapeutic areas, including
allergy, opioid overdose, respiratory and inflammatory disease. The
Company’s SYMJEPI® (epinephrine) Injection products are approved by
the FDA for use in the emergency treatment of acute allergic
reactions, including anaphylaxis. The Company’s ZIMHI™ (naloxone)
Injection product is approved for the treatment of opioid overdose.
Tempol is in development for the treatment of patients with
COVID-19 and a Phase 2/3 clinical trial is underway. For additional
information about Adamis Pharmaceuticals, please visit our website
and follow us on Twitter and LinkedIn.
Contact:
Adamis Investor Relations Robert UhlManaging DirectorICR
Westwicke 619.228.5886robert.uhl@westwicke.com
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024
Real-Time news about Adamis Pharmaceuticals Corporation (NASDAQ): 0 recent articles
Más de Artículos de Noticias